Background: PCI of long lesions is associated with a lower clinical success rate, and higher complication and restenosis rates compared with shorter lesions. The use of DES should improve the outcome of the treatment of long lesions. Recently,very long DES have become available, thus avoiding the need for multiple stenting with overlap. Methods: We set up a registry of 500 consecutive patients treated only with 28, 32 and 38 mm TAXUS Element (TE) stents,in 33 French hospitals. The primary endpoint (PE) of the trial was the MACE rate at 12 months: composite of cardiac death, myocardial infarction (MI) and target vessel revascularisation (TVR). Secondary Endpoints (SE): MACE rate at 6 and 36 month (mo).Each individual MACE component, any MI, any TVR at 6,12 and 36 mo. Stent Thrombosis at 36 mo.Cost Effectiveness analysis at 1 year (yr). Inclusion criteria: age ≥18 yrs, angioplasty performed with a TE stent of 28,32 and 38 mm length (up to 3 in occlusive dissection),presence of one or a combination of following pathologies: diabetes,small vessels (O 15mm), CTO, restenosis in BMS, Acute Coronary Syndromes/AMI in pts with a high risk for restenosis.All data were gathered, monitored,adjudicated and analysed by an independent organisation. Results: From April 2011 to December 2012, 487 patients underwent PCI with long TE stents. Mean age was 64.3±11.5 yrs, 17.3% were female, 39.7% were diabetics and 60.8% smokers. 40% of the patients had single vessel- and 60% multivessel disease.PCI indication was ACS for 41.6% of pts (STEMI: 9,4%), stable angina or silent ischemia in the remaining, CTO recanalization in 12.9% and restenosis in BMS in 8.7% of the patients. Radial approach was performed in 72.9% of the index procedures, in 6F (81,1%). Target vessel was LAD in 43.2%. Direct stenting was performed in 37.5% of the patients. Mean stent rate was 1.2 stent/pt; 17.8% of lesions involved a bifurcation (provisional T-stenting in 38.4%).During PCI, Heparin was administered in 89,3% (UFH: 68,5%), Aspirin in 96,8%, Clopidogrel in 79,7%, Prasugrel in 22,8% and GP IIb/IIIa inhibitors in 12,4% of the pts.Procedural success rate was 99.6%. In-hospital complications included 3 deaths (0.6%), of which 2 were of cardiac origin (0.4%), 3 cases of AMI (0.6%) and 2 TVR (0.4%), resulting in a MACE rate of 1.4%. Conclusion: Treatment of long coronary lesions with Long DES (TAXUS Element 28, 32 and 38mm) is feasible with a high procedural success- and low in-hospital complication rate. The primary endpoint results of the trial will be available at the meeting.